Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Enanta Pharmaceuticals (ENTA) PT Lowered to $90 at RBC Capital
August 8, 2018 8:33 AM EDTRBC Capital lowered its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $90.00 (from $111.00) while maintaining a Sector Perform rating.
... MoreEnanta Pharma (ENTA) Misses Q3 EPS by 1c
August 7, 2018 4:04 PM EDTEnanta Pharma (NASDAQ: ENTA) reported Q3 EPS of $0.97, $0.01 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.93 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
... More